Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic…
NCT00003984 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Withdrawn
Key facts
| NCT number | NCT00003984 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome |
| Official title | Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | lintuzumab |
| Enrollment | 0 |
| Start date | Feb 1, 1999 |
| First posted | May 25, 2004 |
| Last update posted | Jul 11, 2012 |
| Countries | Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: